Polaris Venture Management Co. V, L.L.C. - Q3 2018 holdings

$200 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 12 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .

 Value Shares↓ Weighting
FATE  Fate Therapeutics, Inc.$40,288,000
+43.6%
2,473,1860.0%20.17%
+32.0%
STIM  Neuronetics, Inc.$26,442,000
+20.5%
824,7650.0%13.24%
+10.7%
SELB  Selecta Biosciences, Inc.$24,986,000
+17.4%
1,606,8130.0%12.51%
+7.8%
KALA  Kala Pharmaceuticals, Inc.$18,334,000
-28.1%
1,857,5820.0%9.18%
-34.0%
TTOO  T2 Biosystems, Inc.$13,722,000
-3.8%
1,841,9240.0%6.87%
-11.6%
TRVN  Trevena, Inc.$4,354,000
+47.2%
2,053,5400.0%2.18%
+35.3%
ASNS  Arsanis, Inc.$3,028,000
-55.4%
1,868,9570.0%1.52%
-59.0%
GNCA  Genocea Biosciences, Inc.$1,535,000
-8.9%
1,968,6060.0%0.77%
-16.3%
LIFE  Atyr Pharma Inc.$1,485,000
-10.7%
1,827,9920.0%0.74%
-18.0%
PULM  Pulmatrix, Inc.$1,330,000
-17.7%
3,594,3810.0%0.67%
-24.4%
DARE  Dare Bioscience, Inc.$318,000
-16.8%
326,2430.0%0.16%
-23.6%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Fate Therapeutics, Inc.30Q2 202179.2%
Atyr Pharma Inc.26Q3 202115.1%
Trevena, Inc.22Q2 201924.9%
Genocea Biosciences, Inc.21Q1 201932.5%
Selecta Biosciences, Inc.20Q1 202139.5%
T2 Biosystems, Inc.20Q2 201936.1%
Dare Bioscience, Inc.17Q3 20213.9%
Pulmatrix, Inc.16Q1 201915.4%
Cerulean Pharma Inc13Q2 201716.2%
Kala Pharmaceuticals, Inc.11Q1 202037.1%

View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.

Latest filings
TypeFiled
32022-03-30
13F-HR2021-11-12
13F-HR2021-08-12
13F-HR2021-05-12
13F-HR2021-02-12
13F-HR2020-11-12
13F-HR2020-08-12
13F-HR2020-05-14
42020-05-06
32020-04-30

View Polaris Venture Management Co. V, L.L.C.'s complete filings history.

Compare quarters

Export Polaris Venture Management Co. V, L.L.C.'s holdings